TrialScientific reports2025

Osimertinib plus chemotherapy versus osimertinib for patients with advanced NSCLC with concomitant EGFR and TP53 mutations: a prospective cohort study.

Jixian Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.